MacroGenics Inc
Change company Symbol lookup
Select an option...
MGNX MacroGenics Inc
CBZ CBIZ Inc
PSEC Prospect Capital Corp
SPEC Spectralcast Inc
RC Ready Capital Corp
GNK Genco Shipping & Trading Ltd
NVOS Novo Integrated Sciences Inc
PDRDF Pernod Ricard SA
RKDA Arcadia Biosciences Inc
BBVA Banco Bilbao Vizcaya Argentaria SA
Go

Health Care : Biotechnology | Small Cap Value
Company profile

MacroGenics, Inc. is a biopharmaceutical company that is focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. It is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.

Closing Price
$3.98
Day's Change
0.08 (2.05%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.15
Day's Low
3.79
Volume
(Below Average)
Volume:
815,561

10-day average volume:
1,005,652
815,561

Wells Fargo profit grows, shares rise in premarket

7:10 am ET January 14, 2022 (MarketWatch)
Print

Wells Fargo & Co. (WFC) said Friday its fourth-quarter profit increased to $5.75 billion, or $1.38 a share, from $3.09 billion, or 66 cents a share in the year-ago quarter. Revenue increased to $20.86 billion from $18.49 billion. The San Francisco-based banking giant was expected to earn $1.11 a share on revenue of $18.79 billion, according to a FactSet survey of Wall Street analysts. "The changes we've made to the company and continued strong economic growth prospects make us feel good about how we are positioned entering 2022," CEO Charlie Scharf said. "But we also remain cognizant that we still have a multiyear effort to satisfy our regulatory requirements - with setbacks likely to continue along the way - and we continue our work to put exposures related to our historical practices behind us." The stock rose 1% in premarket trades. Wells Fargo shares have risen 16.7% so far in 2022, compared to a loss of 2.3% by the S&P 500.

-Steve Gelsi

	

(END) Dow Jones Newswires

January 14, 2022 07:10 ET (12:10 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.